SLC16A4 Antibody

說明書

中文名稱：

SLC16A4兔多克隆抗體
貨號：

CSB-PA968241
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using CSB-PA968241(SLC16A4 Antibody) at dilution 1/80, on the right is treated with synthetic peptide. (Original magnification: ×200)

Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal muscle tissue, Primary antibody: CSB-PA968241(SLC16A4 Antibody) at dilution 1/1200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

O15374
基因名：

SLC16A4
別名：

SLC16A4 antibody; MCT4 antibody; MCT5 antibody; Monocarboxylate transporter 5 antibody; MCT 5 antibody; Monocarboxylate transporter 4 antibody; MCT 4 antibody; Solute carrier family 16 member 4 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Synthetic peptide of Human SLC16A4
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:10000
WB	1:1000-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

功能：

Proton-linked monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate.
基因功能參考文獻(xiàn)：
1. MCT4 knockdown reduced the activation of Akt and increased Bax/Bcl-2 ratios, cytochrome c release and caspase-3 cleavage.Consequently, MCT4 could serve as a promising biomarker for esophageal squamous cell carcinoma to identify patients with poor prognosis PMID: 30226548
2. High MCT-4 expression is associated with clear cell renal cell carcinoma. PMID: 29657088
3. Nrf2 overexpression upregulated MCT1, but decreased MCT4 expression in premalignant and malignant colonic epithelial cells. PMID: 28846107
4. These results demonstrate that Monocarboxylate transporters tend to play a role in the aggressive breast cancer subtypes through the dynamic interaction between breast cancer cells and adipocytes. PMID: 29775610
5. Elevated MCT4 protein expression in clinical prostate cancer specimens was associated with increases in Gleason grade, prolonged treatment of patients with neoadjuvant hormone therapy, castration resistant prostate cancer, and early disease relapse. PMID: 26755530
6. our finding that the expression of MCT1 and MCT4 is reduced in mutant IDH1 gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 tumors and has important implications for our understanding of these tumors and their treatment PMID: 27144334
7. Results suggest that MCT4 plays a central role in tumor metabolism in gastric cancer (GC) with peritoneal carcinomatosis and targeting MCT4 in combination with chemotherapy could be a novel strategy in the treatment of GC. PMID: 27224918
8. TOMM20, MCT1, and MCT4 expression was significantly different in Hodgkin and Reed Sternberg (HRS) cells. High MCT4 expression was found in tumor associated macrophages, but absent in HRS cells in all but one case. Tumor-infiltrating lymphocytes had absent MCT4 expression. Reactive lymph nodes in contrast to cHL tumors had low TOMM20, MCT1, and MCT4 expression in lymphocytes and macrophages. PMID: 29248133
9. Stromal cells in diffuse large B-cell lymphoma samples strongly expressed MCT4, displaying a glycolytic phenotype, a feature not seen in stromal elements of non-neoplastic lymphatic tissue. PMID: 29248132
10. The structures and functions of hMCT1 and hMCT4 transporters. PMID: 28559188
11. MCT1 inhibitor AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux. PMID: 28923861
12. The reversible H(+)/lactate(-) symporter MCT4 cotransports lactate and proton, leading to the net extrusion of lactic acid in glycolytic tumors. A model of its role in pH control in tumor cells is described. Review. PMID: 26944480
13. Increased miR-210 and concomitant decreased ISCU RNA levels were found in ~40% of tumors and this was significantly associated with HIF-1alpha and CAIX, but not MCT1 or MCT4, over-expression. PMID: 28099149
14. High expression of MCT4 is associated with inflammation in arsenite-induced liver carcinogenesis. PMID: 28419250
15. The loss expression of Cav-1 on CAFs and the up-regulation of MCT4 may be the possible mechanisms of CAFs in tumorigenesis. PMID: 28625953
16. MCT1 and MCT4 expression levels were associated with worse prognosis and shorter overall survival. PMID: 27105345
17. We demonstrated that the expression levels of glycolysis-related proteins glucose transporter 1, hexokinase II, carbonic anhydrase IX, and monocarbonylate transporter 4 differ between thyroid cancer subtypes and are correlated with poorer prognosis PMID: 28347233
18. Data suggest that inhibition of mnocarboxylate transporters MCT1 and MCT4 may have clinical relevance in pancreatic ductal adenocarcinoma (PDAC). PMID: 26765963
19. MCT1 inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 and MCT4 via disruption of pyruvate rather than lactate export. PMID: 26876179
20. MCT1 expression was not clearly associated with overall or disease-free survival. MCT4 and CD147 expression correlate with worse prognosis across many cancer types. These results warrant further investigation of these associations PMID: 26779534
21. Prognostic significance of CD147 protein expression could not surpass that of MCT4, especially of SLC16A3 DNA methylation, corroborating the role of MCT4 as prognostic biomarker for ccRCC. PMID: 26384346
22. MCT4 expression is regulated by the PI3K-Akt signalling pathway and highly expressed in HER2-positive breast cancers where it regulates tumor cell metabolism and survival. PMID: 25965974
23. Knockdown of MCT4 blocks lactate efflux to result in lactic acid accumulation and pH dropping, which is involved in triggering apoptosis in HUVECs. PMID: 26363456
24. we showed that genetic disruption of Mct4 and/or Ampk dramatically reduced tumourigenicity in a xenograft mouse model suggesting a crucial role for these two actors in establishment of tumours in a nutrient-deprived environment PMID: 26059436
25. synovial fibroblasts from patients with rheumatoid arthritis exhibited up-regulated transcription of MCT4 mRNA compared with osteoarthritis patients. Knockdown of MCT4 induced intrinsic apoptosis of fibroblasts, thereby inhibiting their proliferation. PMID: 26213210
26. The first IF method has been developed and optimised for detection of MCT 1 and MCT4 in cancer patient circulating tumour cells . PMID: 25957999
27. Findings demonstrate that the histidine residue His382 in the extracellular loop of the transporter is essential for pH regulation of MCT4-mediated substrate transport activity. PMID: 25919709
28. Decreased astroglial monocarboxylate transporter 4 expression in temporal lobe epilepsy PMID: 24464262
29. MCT4 expression can predict survival and trans-arterial chemoembolization treatment response for hepatocellular carcinoma patients. MCT4 plays a role in cell proliferation and migration/invasion. PMID: 25446815
30. we sought to evaluate the associations of nine functional SNPs in genes encoding MCT1, MCT2, and MCT4 with the prognosis in a cohort of 500 Chinese NSCLC patients. PMID: 25578492
31. High monocarboxylate transporter 4 protein expression in stromal cells is associated with invasiveness in gastric cancer. PMID: 25374230
32. These results indicate there are no additional benefits of IHT when compared to similar normoxic training. Hence, the addition of the hypoxic stimulus on anaerobic performance or MCT expression after a three-week training period is ineffective. PMID: 24797797
33. MCT4 upregulation correlated with the aggressive mesenchymal subset of glioblastoma (GBM), and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. PMID: 24077291
34. MCT4 is up-regulated in inflammation-activated macrophages and required for innate immune response. PMID: 25406319
35. Aberrant expression of MCT4 in carcinoma cells serves as a novel, independent prognostic factor for HCC, indicating a poorer patient outcome. PMID: 24433439
36. MCT4 demonstrated the strongest deleterious impact on survival in triple negative breast cancer patients.MCT4 should serve as a new prognostic factor in node-negative breast cancers. PMID: 25058459
37. The critical role of MCT4 in cell proliferation. PMID: 24498219
38. Upregulation of MCT4 expression via SLC16A3 promoter DNA methylation is associated with clear cell renal cell carcinoma. PMID: 23881922
39. Results suggest that Arginine-278 in transmembrane-spanning domains TMD8 is a critical residue involved in L-lactate recognition by monocarboxylate transporter 4 (hMCT4). PMID: 23935841
40. Coexpression of CAIV with MCT1 and MCT4 resulted in a significant increase in MCT transport activity. PMID: 24338019
41. Alterations in Cav-1 and MCT4 expression may mark a critical point in the progression from in situ to invasive breast cancer. PMID: 23907124
42. MCT1 and MCT4 biomarkers were employed to determine the metabolic state of proliferative cancer cells. PMID: 23574725
43. High MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor. PMID: 23780984
44. Overexpression of MCT4 is associated with gliomas. PMID: 23258846
45. Report SNPs in MCT4 (SLC16A3) gene in the Chinese and Indian populations of Singapore. PMID: 22240841
46. Combined application of GLUT-1, MCT-1, and MCT-4 immunohistochemistry might be useful in differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. PMID: 23187830
47. High GLUT1 plus high MCT4 expression indicated an aggressive tumor behavior in adenocarcinomas. PMID: 22153830
48. Data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in renal cell carcinoma. PMID: 22362593
49. Data show that a significant increase of MCT2 and MCT4 expression in the cytoplasm of tumour cells and a significant decrease in both MCT1 and CD147 expression in prostate tumour cells was observed when compared to normal tissue. PMID: 21787388
50. both MCT1 and CD147, but not MCT4, were associated with GLUT1 and CAIX expression in a large series of invasive breast carcinoma samples PMID: 21870331
顯示更多

收起更多
亞細(xì)胞定位：

Cell membrane; Multi-pass membrane protein.
蛋白家族：

Major facilitator superfamily, Monocarboxylate porter (TC 2.A.1.13) family
數(shù)據(jù)庫鏈接：

HGNC: 10925

OMIM: 603878

KEGG: hsa:9122

UniGene: Hs.351306

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human